J&J Coated Stent Launch Expected In All International Markets By May 20
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson must provide regular updates on the long-term performance of its Cypher drug-eluting coronary stent to the British Standards Institution (BSI) following CE mark approval April 12. No postmarket study is required
You may also be interested in...
Preliminary Data From J&J SIRIUS Coated Stent Trial Consistent With RAVEL
Data from the first 400 patients in Johnson & Johnson's U.S. SIRIUS trial of the Cypher sirolimus-eluting coronary stent appear consistent with positive European data from the RAVEL trial, despite inclusion of a larger and sicker patient cohort
Preliminary Data From J&J SIRIUS Coated Stent Trial Consistent With RAVEL
Data from the first 400 patients in Johnson & Johnson's U.S. SIRIUS trial of the Cypher sirolimus-eluting coronary stent appear consistent with positive European data from the RAVEL trial, despite inclusion of a larger and sicker patient cohort
J&J Cypher Royalties To Drive SurModics Projected Growth Of 20-25% In 2002
Royalties from Johnson & Johnson/Cordis' Cypher drug-eluting stent sales are expected to drive SurModics' fiscal 2002 top line growth "in the 20 to 25% range," SurModics says